BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33507515)

  • 21. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
    Yamshon S; Martin P
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and emerging therapies in mantle cell lymphoma.
    Brett LK; Williams ME
    Curr Treat Options Oncol; 2013 Jun; 14(2):198-211. PubMed ID: 23512567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel agents in mantle cell lymphoma.
    Kumar A
    Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
    Zaja F; Federico M; Vitolo U; Zinzani PL
    Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Treatments in Mantle Cell Lymphoma.
    Avyakta Kallam Md ; Vose JM
    Oncology (Williston Park); 2023 Aug; 37(8):326-333. PubMed ID: 37616519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
    Yoon DH; Cao J; Chen TY; Izutsu K; Kim SJ; Kwong YL; Lin TY; Thye LS; Xu B; Yang DH; Kim WS
    J Hematol Oncol; 2020 Mar; 13(1):21. PubMed ID: 32183871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of older patients with mantle cell lymphoma in the era of novel agents.
    Rozental A; Jim HSL; Extermann M
    Leuk Lymphoma; 2023 Sep; 64(9):1514-1526. PubMed ID: 37357622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should there be a standard therapy for mantle cell lymphoma?
    Smith MR
    Future Oncol; 2011 Feb; 7(2):227-37. PubMed ID: 21345142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
    Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
    Wallace D; Reagan PM
    Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for mantle cell lymphoma.
    Smolewski P; Witkowska M; Robak T
    Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.